News & Events
 
The Drugs Technical Advisory Board has examined the issue of suspension of manufacture and sale of Pioglitazone on 19th July 2013 & has recommended that the Suspension of the drug should be revoked and allowed to be marketed subject to certain conditions the manufacturers shall mention on their package insert and promotional literature of the drug. Based on DTAB report Ministry of health & family welfare & Central Government revokes the notification G.S.R.379(E) dated 18th June 2013.
-------------------------------
A new study presented at EULAR 2013,the Annual Congress of the European League Against Rheumatism shows that one in eight patients at risk of developing a serious adverse drug event (ADE) is taking over the counter (OTC) non-steroidal anti-inflammatory drugs (NSAIDs), often to treat a musculoskeletal complaint Possible serious ADEs include gastrointestinal bleeding, peptic ulceration, high blood pressureand worsening heart failure.
-------------------------------
Researchers reported at the American Heart Association's 50th Annual Conference on Cardiovascular Disease Epidemiology and Prevention, that the increase in sugar consumption has led to more diabetes and heart disease over the past decade.
-------------------------------
People taking statin drugs to lower their cholesterol may slightly increase their risk for muscle and joint diseases as well as strains and sprains, a new study suggests.The results were published online June 3 in the journal JAMA Internal Medicine.

Testimonials
Slideshow Image 1
Slideshow Image 2
Slideshow Image 1
Slideshow Image 2
Slideshow Image 1
 
     
 
Telmisartan & Hydrochlorothiazide Tablets

 
  COMPOSITION:  
  Each uncoated tablet contains Telmisartan IP 40 mg & Hydrochlorothiazide IP 12.5 mg.  
     
  THERAPEUTIC INDICATIONS:  
  Indicated for the treatment of essential hypertension as second line therapy.  
     
  DOSAGE AND ADMINISTRATION:  
 
The usual starting dose of telmisartan is 40 mg once a day; blood pressure response is dose related over the range of 20-80 mg. Hydrochlorothiazide is effective in doses of 12.5 mg to 50 mg once daily. Telsite H tablets may be administered once daily with or without food.
 
     
  CONTRAINDICATIONS :  
 
Contraindicated in patients who are hypersensitive (e.g., anaphylaxis or angioedema) to telmisartan or hydrochlorothiazide or any other component of the product. Contraindicated in patients with anuria orhypersensitivity to other sulfonamide-derived drugs.
 
     
  WARNINGS & PRECAUTIONS:  
 
Telmisartan can cause fetal/neonatal morbidity and mortality when administered to pregnant women. Hypotension may occur in patients who are intravascular volume- or sodium-depleted. Hydrochlorothiazide should be used in caution in patients with impaired hepatic function or progressive liver disease. Hypersensitivity reactions to hydrochlorothiazide may occur in patients with or without a history of allergy or bronchial asthma. May cause exacerbation or activation of systemic lupus erythematosus. Lithium should not be given with thiazides. Hydrochlorothiazide can cause an idiosyncratic reaction resulting in acute transient myopia and acute angle closure glaucoma.
 
     
  Back to Products  

 

 

         
 
 
Home | About Us | Products | Enquiry | Contact Us | Order | Carrer
     
  All Rights Reserved By : Cadell Health care Pvt Ltd. Designed & Maintained By : Daffodil Design & Prints